华东医药：DR10624已被纳入突破性治疗药物程序

Core Viewpoint - Huadong Medicine (000963) has received recognition from the National Medical Products Administration (NMPA) for its product DR10624, which is now included in the breakthrough therapy designation program for severe hypertriglyceridemia, indicating the regulatory body's acknowledgment of the product's clinical value [1] Group 1 - The inclusion of DR10624 in the breakthrough therapy program will facilitate a shorter review timeline for the product [1] - The company plans to continue advancing the clinical research of DR10624, adhering strictly to data results and regulatory guidance to determine the most appropriate submission strategy [1] - Specific plans and progress will be communicated through official company announcements [1]